The first total synthesis of the n-3 docosapentaenoic derived oxygenated product MaR2 n-3 DPA has been achieved. The 13R and 14S stereogenic centers were introduced using 2-deoxy-D-ribose in a chiral pool strategy. The geometry of the Z,E,E-triene moiety was prepared using highly E-selective Wittig-and Takai-olefination reactions as well as the Z-stereoselective Lindlar reduction. LC/MS-MS data of synthetic MaR2 n-3 DPA matched data for the biosynthetic formed product that enabled the configurational assignment of this oxygenated natural product to be (7Z,9E,11E,13R,14S,16Z,19Z)-13, 14-dihydroxydocosa-7,9,11,16,19-pentaenoic acid. 
docosahexaenoic acid (DHA) in the presence of 12-lipoxygenase and was the first member of the maresin family of SPMs to be reported 4 and prepared by total synthesis. 5 In 2013 Dalli and co-workers reported several new SPMs biosynthesized from n-3 docosapentaenoic acid (n-3 DPA). 6 n-3 DPA, consisting of 22 carbons and five all-Z double bonds, is an elongated product of eicosapentaenoic acid and an intermediate in the biosynthesis of DHA. 7 Using a self-limited model of inflammation and targeted metabololipidomics during the onset and resolution of acute inflammation, Dalli and coworkers 6 uncovered several novel n-3 DPA SPMs that are potent bioactive molecules. The structures of MaR1 n-3 DPA (1), MaR2 n-3 DPA (2) and MaR3 n-3 DPA (3) are shown in Figure. 1. Based on their novel pro-resolving and anti-inflammatory bioactions, SPMs have attracted significant interest from the biomedical, pharmacological and synthetic organic communities. 8 SPMs act as agonists on individual GPCRs 9 exhibiting nanomolar proresolution and anti-inflammatory bioactions. 10 Some SPMs have entered initial clinical trial development programs. 11 These endogenously formed products are available in minute amounts from their natural sources and contain several stereogenic centers and conjugated Eand Z-double bonds. Hence, stereoselective synthesis for configurational assignment and extensive biological testing becomes necessary.
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A few of the n-3 DPA-derived SPMs have recently been prepared 12 and subjected to biological evaluations, 13 but MaR2 n-3 DPA (2) has not been synthesized to date and its absolute configuration at C-13 remained to be determined. These facts, as well as the high demand for sufficient material for biological and pharmacological testing, inspired us to report the first total synthesis of MaR2 n-3 DPA (2).
The three key intermediates 4, 5 and 6 in our retrosynthetic analysis are depicted in Scheme 1. The stereogenic centers at C13 and C14 were assumed to be R and S, respectively, based on biosynthetic considerations. 6 Hence, 2-deoxy-D-ribose (7) The phosphonium salt 8 was synthesized from Z-hex-3-en-1-ol (9) as previously described. 12c Intermediate 11 was obtained from known TBS-protected aldehyde 10 12d using a highly Z-selective Wittig reaction with the in situ generated ylide of 8 (Scheme 2). This produced 11 as one diastereomer in 84% yield (ESI). Next, a selective deprotection of the primary TBS-group in 11 was achieved with para-toluene sulfonic acid (PTSA) in MeOH at -20 o C giving alcohol 12 that was oxidized (Dess-Martin periodinane (DMP), NaHCO 3 , CH 2 Cl 2 ) to its aldehyde 13 in 40% yield over the two steps. Aldehyde 13 was dissolved in toluene and 1.3 equiv. of the stabilized ylide (triphenyl-phosphoranylidene)acetaldehyde was added. The reaction mixture was heated at reflux for 19 hours to afford the E-configured α,β- Using multiple reaction monitoring (MRM) of the on parent ion with m/z 361 and the daughter ions m/z 223 or m/z 193, we obtained a sharp peak with retention time (R T ) of 14.4 min ( Fig. 2A) . Of note, a similar retention time of 14.4 min was obtained with synthetic 2 (see Fig. 2A ). Moreover, co-injection (2 µL) of a homogenous sample of biological MaR2 n-3 DPA (2) with synthetic 2 in a 1:10 molar ratio, respectively, gave a single sharp peak in MRM experiments, with R T 14.4 min ( Fig. 2A) . Similar findings were made with platelet rich plasma, where endogenous MaR2 n-3 DPA (5) gave a R T of 14.4 min that co-eluted with synthetic 2 (Fig. 2B) . To obtain further evidence that the chemical structure for synthetic 2 matches that of endogenous MaR2 n-3 DPA we next assessed the MS/MS fragmentation spectra.
Here we found that, in accordance with published findings, 6 The SPMs are among the most exciting small and naturally occurring molecules currently undergoing investigations towards drug development of new anti-inflammatory drugs. 1, 16 The stereoselective synthesis of 2 using the Lindlar reaction, the Sonogashira coupling reaction and the Takai olefination produced multi milligram quantities of 2 that is now available for further biological and pharmacological evaluations to be conducted.
